Myriad enters neuroscience with $225M Assurex Health buy

Myriad Genetics ($MYGN) is jumping into the neuroscience market with a $225 million acquisition of Assurex Health, which does genetic testing for psychotropic medicine selection. Assurex has the potential to pick up an additional $185 million if it meets certain performance-based milestones.

The Assurex buy will add the Mason, OH-based company’s GeneSight genetic test to Myriad’s stable. The test uses a patient's DNA collected via cheek swab and provides information to help healthcare providers select medications in a personalized approach. The addition will allow Myriad to join the neuroscience market, in which the U.S. spends more than $150 million in direct healthcare costs.

The buy will give Myriad access to the more than 76 million people in the U.S. who have some form of mental disorder and also serves as a launchpad for the company’s in-development neuroscience offerings, including myPath Bipolar, a differential diagnosis tool for bipolar disorder and major depressive disorder.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

"Assurex provides Myriad access to GeneSight one of the fastest growing new diagnostic tests ever in a multi-billion dollar global market and builds upon Myriad's commitment to expand into neuroscience, positioning us for long-term growth," said Myriad CEO Mark Capone in a statement. "Importantly, this acquisition provides an experienced commercial organization in the neuroscience market that we believe will be one of the highest growth areas for personalized medicine and completes our infrastructure expansion consistent with our four-in-six strategy."

Myriad expects to close the transaction by the end of Q1 2017 and will discuss the deal’s effects on its financials on its Q4 earnings call next week. It follows Myriad’s acquisition of Sividon Diagnostics, a Siemens spinout that markets the prognostic EndoPredict breast cancer test.

- read the statement

Related Articles:
Myriad buys predictive breast cancer Dx startup Sividon for up to €50M
Myriad extends companion Dx deal with AstraZeneca to pancreatic cancer
Myriad extends collaboration with BioMarin for cancer companion Dx

Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.